The novel therapy of pulmonary hypertension by preventing right heart failure

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19409
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: Yamaguchi University
• Principal Investigator: ONO Makoto 山口大学, 医学部附属病院, 診療助教(4日/週) (50650321)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: カルモジュリン / リアノジン受容体 / 肺高血圧

Outline of Final Research Achievements

PAH mice and Sham mice were orally administered the Ca leak inhibitor dantrolene, and the right ventricular pressure was measured, the cardiomyocyte size was measured, Ca transient observation, fixed and anti-CaM, anti-GRK 5, anti-HDAC 4, 5, anti Immunostaining was performed with antibodies of -p-HDAC 4, 5. As a result, oral administration of dantrolene did not affect pulmonary artery pressure. In the oral administration group of dantrolene, myocardial cell size was reduced and the hypertrophy was suppressed. Furthermore, reduction of RyR bound CaM was suppressed. From this, it was suggested that dantrolene inhibited the dissociation of CaM from RyR, thus suppressing hypertrophy.

Free Research Field

循環器内科学